Learn About Double Up Shot A provider-guided weight-management program that starts with your health history and builds realistic support around your needs

When you should wait vs act now: the decision framework Wait if: Your insurance copay is under $200/month and you're comfortable with that cost You're within 3 months of meeting your deductible (after which your copay drops significantly) You're enrolled in a clinical trial for tirzepatide (free medication) You qualify for Eli Lilly's patient assistance program (income-based free medication) You're willing to delay treatment 3 to 5 years for biosimilar entry Act now with brand-name Zepbound if: Your insurance covers it with a copay under $150/month You strongly prefer FDA-approved medications You want pen convenience over vial-and-syringe You've tried compounded tirzepatide and experienced supply inconsistency Act now with LillyDirect vials if: You're self-pay and want brand-name medication Your insurance copay exceeds $549/month You're comfortable with self-injection You don't qualify for compounded tirzepatide (some states restrict access) Act now with compounded tirzepatide if: Your insurance doesn't cover Zepbound for weight loss Your copay exceeds $250/month You want the lowest current cost option You're comfortable with non-FDA-approved medication prepared by a licensed compounding pharmacy The cost-of-waiting calculation: Waiting 3 years (2026 to 2029) for potential biosimilar entry costs $11,760 to $38,160 in foregone treatment, depending on your current option

248,251,252 This mechanism is particularly evident in the use of GLP-1-based drugs, such as GLP-1RAs, in the treatment of T2DM
Brand-name medications have no listed prices
The monthly plan at $249 stands alone, multi-month discounts are positioned as opt-in rather than the default, and pricing is published transparently before you complete the intake
Timing GLP-1 injections around exercise Exercise timing relative to your GLP-1 injection can affect both performance and side effect management